Our mission is to disrupt the field of surgery and positively impact the lives of patients through the development of our platform of biomorphic programmable polymers
TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function.
Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.
Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.
We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.
TISSIUM is founded
Technology transfer of our first polymer: PGSA
Publication featuring the TISSIUM platform in Science Translational Medicine
Design of our first accessories
ISO certification of TISSIUM
Blue Seal clinical trial completed
TISSIUM platform expansion to new surgical fields
First CE Mark granted for vascular sealant
TISSIUM platform expansion to 3D printing
ISO certification of manufacturing facility in Roncq, France
TISSIUM platform expansion to peripheral nerve repair
TISSIUM platform expansion into drug delivery
CE Mark granted for vascular sealant in pre-filled syringe format
Meet our leadership team
Co-Founder, Chief Executive Officer
Christophe Bancel is Co-founder and CEO of TISSIUM. Prior to founding the company, he has held corporate and strategic leadership positions at UCB and Serono and was Co-founder and Business Development Director at Domain Therapeutics. Christophe holds a MSc in Engineering from Ecole Centrale Paris, a MSc in Molecular Biology from the University of Tokyo, and an MBA from INSEAD.
Maria Pereira leads the Innovation Hub at TISSIUM. She co-invented the technology while a PhD student at Prof. Jeff Karp’s Laboratories. She has been recognized for her research by MIT Tech Review’s “35 Innovators Under 35” in 2014, as well as Forbes in its “30 under 30” selection in Healthcare in 2015. Maria holds a PhD in Bioengineering from the MIT-Portugal program and an MBA from INSEAD.
Brice Epry leads TISSIUM’s Corporate, Human Resources and General Administration activities. He has over 15 years of experience in cross-functional roles at medium and large companies including Distrilogie, Eurovia and UCB. During his tenure at UCB, Brice held leadership roles in Controlling, Business Intelligence, and Brand Management. Brice holds a BSc in Business Administration from EDC Paris Business School with a specialization in Finance.
Hunt Henrie joined Tissium in early 2021. He is an experienced financial, strategic and biomedical executive with over 30 years of broad-based global financial, investment banking, private equity and corporate C-Level operating experience in public and private healthcare companies. Before joining Tissium Hunt created Sachuest Partners, a strategic advisory firm focused on building leading MedTech companies
Thierry Darnis leads the Global Operations at Tissium, (Development & industrialization, Quality, Chemical Characterization and Manufacturing). He has a deep background of more than 30 years as a global leader managing major medical device design and production units at world-class companies such as Medtronic and CR Bard but also at innovative startups. Thierry holds a PhD in Biology and Health, specializing in Biomaterials from the University of Bordeaux II.
Vice President of Global Regulatory and Clinical Affairs
Seth Schulman is the V.P. of Global Regulatory and Clinical Affairs for Tissium. Seth has over 25 years experience in the medical device field. Prior to Tissium, Seth was V.P. of Regulatory Affairs at Penumbra, Inc, growing the Regulatory team and transitioning the team to a region based model. Prior to Penumbra, Inc. Seth held positions of increasing responsibility at US Surgical, Boston Scientific, Innercool Therapies, Medtronic and Genzyme. Seth holds a B.S. Biology from Tufts University.
Romain is CFO of Tissium. Prior to joining Tissium, Romain spent 11 years working in Corporate Finance at ODDO BHF. Most recently, he served as Managing Director and head of Public M&A / ECM France. He supported numerous IPOs as well as capital increases, delistings, takeovers and other M&A transactions. Romain holds a MSc in Engineering from Ecole Centrale Lille, a Master in Strategy & Management of International Business from ESSEC Business School and did an exchange program at Thunderbird School of Global Management.
Ruth Krestin is the VP of Portfolio Strategy at Tissium. Ruth has over 11 years of experience in the pharma industry. After starting her career in strategy consulting at PwC, Ruth most recently spent 6 years at AstraZeneca, holding roles of increasing responsibility in both R&D and commercial, including portfolio management, business insights and competitive intelligence. Ruth holds a MSc in Technology Policy from MIT and a BSc in Life Science from University College Utrecht.